• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Met受体的一种可变剪接形式具有致瘤性。

An alternatively spliced form of Met receptor is tumorigenic.

作者信息

Lee Jae-Ho, Gao Chong Feng, Lee Chong Chou, Kim Myung Deok, Vande Woude George F

机构信息

Department of Biochemistry, School of Medicine, Ajou University, Suwon 443-721, Korea.

出版信息

Exp Mol Med. 2006 Oct 31;38(5):565-73. doi: 10.1038/emm.2006.66.

DOI:10.1038/emm.2006.66
PMID:17079873
Abstract

The Met tyrosine kinase receptor is a widely expressed molecule, which mediates pleiotropic cellular responses following activation by its ligand, hepatocyte growth factor/scatter factor (HGF/SF). Previously, one of the authors identified an alternatively spliced form of Met (Met-SM) that lacked a single exon of a 47-amino-acid segment in the juxtamembrane domain. Here we report that Met-SM is a potent transforming gene in NIH3T3 mouse fibroblast cells. Met-SM-transfected NIH3T3 cells show stronger foci-forming activity than wild type- Met-transfected ones. In addition, Met-SM-transfected NIH3T3 cells form colonies in soft agar and are tumorigenic in athymic nu/nu mice. Furthermore, HGF/SF significantly increases the focus-forming activity of Met-SM comparing to wild type Met. The amount of protein and of tyrosine kinase activity of Met-SM accumulates to a high level following HGF/SF treatment. The accumulation of Met-SM correlated well with its delayed ubiquitination and increased stability. These results are consistent with the important role of the juxtamembrane domain in protein stability of Met receptor and suggest that the alternatively-spliced form may contribute to the development and progression of human cancer.

摘要

Met酪氨酸激酶受体是一种广泛表达的分子,它在被其配体肝细胞生长因子/散射因子(HGF/SF)激活后介导多效性细胞反应。此前,本文作者之一鉴定出一种Met的可变剪接形式(Met-SM),其近膜结构域中缺少一个包含47个氨基酸片段的单一外显子。在此我们报告,Met-SM在NIH3T3小鼠成纤维细胞中是一种有效的转化基因。转染Met-SM的NIH3T3细胞比转染野生型Met的细胞表现出更强的集落形成活性。此外,转染Met-SM的NIH3T3细胞在软琼脂中形成菌落,并且在无胸腺裸鼠中具有致瘤性。此外,与野生型Met相比,HGF/SF显著增加了Met-SM的集落形成活性。HGF/SF处理后,Met-SM的蛋白量和酪氨酸激酶活性积累到高水平。Met-SM的积累与其延迟的泛素化和增加的稳定性密切相关。这些结果与近膜结构域在Met受体蛋白稳定性中的重要作用一致,并表明这种可变剪接形式可能有助于人类癌症的发生和发展。

相似文献

1
An alternatively spliced form of Met receptor is tumorigenic.Met受体的一种可变剪接形式具有致瘤性。
Exp Mol Med. 2006 Oct 31;38(5):565-73. doi: 10.1038/emm.2006.66.
2
Transforming variant of Met receptor confers serum independence and anti-apoptotic property and could be involved in the mouse thymic lymphomagenesis.Met受体的转化变体赋予细胞不依赖血清的特性和抗凋亡特性,并可能参与小鼠胸腺淋巴瘤的发生。
Exp Mol Med. 2004 Aug 31;36(4):283-91. doi: 10.1038/emm.2004.39.
3
A novel germ line juxtamembrane Met mutation in human gastric cancer.人类胃癌中一种新的种系近膜区Met突变
Oncogene. 2000 Oct 12;19(43):4947-53. doi: 10.1038/sj.onc.1203874.
4
HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice.肝细胞生长因子/散射因子(HGF/SF)及其受体c-MET在人B淋巴瘤细胞在重症联合免疫缺陷(SCID)小鼠中的播散过程中起次要作用。
Br J Cancer. 1999 Sep;81(1):43-53. doi: 10.1038/sj.bjc.6690649.
5
A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.一种新型的重组可溶性Met剪接变体是肝细胞生长因子/散射因子-Met通路的有效拮抗剂。
Clin Cancer Res. 2008 Jul 15;14(14):4612-21. doi: 10.1158/1078-0432.CCR-08-0108.
6
Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.针对肝细胞生长因子/分散因子(HGF/SF)的中和性单克隆抗体在动物模型中显示出抗肿瘤活性。
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8. doi: 10.1073/pnas.131200498.
7
The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.散射因子/肝细胞生长因子:c-met通路在人类胚胎中枢神经系统肿瘤恶性肿瘤中的作用
Cancer Res. 2005 Oct 15;65(20):9355-62. doi: 10.1158/0008-5472.CAN-05-1946.
8
Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.正常黑素细胞和黑色素瘤细胞中的Met与肝细胞生长因子/分散因子信号转导
Oncogene. 1992 Nov;7(11):2195-206.
9
SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.SU5416是肝细胞生长因子受体(c-Met)的强效抑制剂,可阻断HGF诱导的人HepG2肝癌细胞的侵袭性。
J Hepatol. 2004 Aug;41(2):267-73. doi: 10.1016/j.jhep.2004.04.013.
10
Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.自分泌肝细胞生长因子/分散因子- Met信号通路诱导C127细胞发生转化并呈现侵袭/转移表型。
Oncogene. 1996 Aug 15;13(4):853-6.

引用本文的文献

1
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.癌症中的MET改变与MET靶向治疗:检测策略、治疗疗效及新兴技术
Target Oncol. 2025 Jul 18. doi: 10.1007/s11523-025-01166-0.
2
Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications.靶向癌症中的c-MET改变:遗传驱动因素与治疗意义综述
Cancers (Basel). 2025 Apr 29;17(9):1493. doi: 10.3390/cancers17091493.
3
Alternative Splicing in Lung Adenocarcinoma: From Bench to Bedside.
肺腺癌中的可变剪接:从实验台到病床
Cancers (Basel). 2025 Apr 15;17(8):1329. doi: 10.3390/cancers17081329.
4
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.在遗传性乳头状肾细胞癌中鉴定出的具有激活型N叶突变的MET变体仍然需要配体刺激。
Mol Oncol. 2025 Feb 20. doi: 10.1002/1878-0261.13806.
5
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.不断变化的非小细胞肺癌预测生物标志物领域。
Pathol Oncol Res. 2024 Jun 17;30:1611733. doi: 10.3389/pore.2024.1611733. eCollection 2024.
6
Recording and classifying MET receptor mutations in cancers.记录和分类癌症中的MET受体突变。
Elife. 2024 Apr 23;13:e92762. doi: 10.7554/eLife.92762.
7
RNA splicing alterations in lung cancer pathogenesis and therapy.肺癌发病机制与治疗中的RNA剪接改变
Cancer Pathog Ther. 2023 Apr 28;1(4):272-283. doi: 10.1016/j.cpt.2023.04.004. eCollection 2023 Oct.
8
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.MET 外显子 14 跳跃突变通过激活 SMAD2 信号转导驱动癌症进展和复发。
Br J Cancer. 2024 Feb;130(3):380-393. doi: 10.1038/s41416-023-02495-5. Epub 2023 Dec 18.
9
An Observatory for the Oncogene: A Guide for Targeted Therapies.癌基因观察站:靶向治疗指南
Cancers (Basel). 2023 Sep 21;15(18):4672. doi: 10.3390/cancers15184672.
10
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.MET 外显子 14 跳跃突变是体外和人源化 HGF 敲入小鼠中肝细胞生长因子 (HGF) 依赖性致癌驱动因素。
Mol Oncol. 2023 Nov;17(11):2257-2274. doi: 10.1002/1878-0261.13397. Epub 2023 Jul 14.